The Recce (ASX: RCE) share price is in the red today despite the company releasing positive data from its latest drug trials.
The post Why is the Recce (ASX:RCE) share price in the red today? appeared first on The Motley Fool Australia. –
It seems shareholders weren’t excited by the results, with the Recce share price dropping from its opening price of 98 cents to close at 97 cents.
Recce is a drug discovery and development business that produces synthetic antibiotics to address the global health challenge of antibiotic-resistant superbugs.
Recce report shows positive sinusitis fight
Recce’s data is from a large trial involving a total of 12 groups of 10 mice each. The study was performed to reveal the efficacy of a new anti-infective formulation, called RECCE 111 (R111), against Streptococcus pneumoniae bacterial sinusitis.
Streptococcus pneumoniae, a gram-positive bacterium (a type of bacterium cell wall), is a leading cause of bacterial pneumonia and meningitis in the United States and a common cause of bloodstream infections, also known as sepsis, ear and sinus infections.
Recce 111 is the title for a wholly-owned experimental compound produced by Recce Pharmaceuticals in-house. The testing showed significant antibacterial capability with no abnormalities detected in any of the 12 groups of mice, with most of the groups administered the drug twice daily.
This news on its own wasn’t enough to send the Recce share price flying today.
Three groups were treated with varying intranasal doses twice daily. These groups showed a significant dose-dependent antibacterial effect when compared to early infection. However, the average efficacy of these doses may be why shareholders appeared uninterested in the company today.
Three groups of mice were treated with varying intravenous doses of up to 1,000 milligrams per kilogram of weight. In contrast, the remaining group of three were treated with intravenous doses up to 250 milligrams per kilogram of weight. Both of these studies revealed relatively similar results.
Azithromycin was the positive control in the study given twice daily at 200 mg/kg and showed a bactericidal effect.
What Recce management said
Recce CEO James Graham said the results were strong for a range of Recce research targets.
We’re continually excited by the potential of Recce’s anti-infective compounds and are encouraged by these positive indications. Moreover, this further enhances the breadth of Recce’s synthetic polymer platform.
Recce share price snapshot
The Recce share price has offered a one-year return of 276% but is down 3.5% this week, 8.5% this month and 9% this year to date. At its current price, Recce has a market capitalisation of $167.7 million.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of February 15th 2021
- Recce Pharmaceuticals (ASX:RCE) share price tumbles despite positive update
- Here’s why the Recce (ASX:RCE) share price is racing higher today
Motley Fool contributor Lucas Radbourne-Pugh has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.